CRKL and non-small cell lung carcinoma: Since no direct pharmacological inhibition of CRKL is presently possible, inhibiting CRKL activation indirectly may provide an effective strategy to enhance the efficacy of ALK inhibitors in patients with ALK-rearranged NSCLC.